Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion

International Journal of Antimicrobial Agents

Volumn 32, Issue 6, 2008, Pages 488-493

  Firsov, Alexander A ^a   Smirnova, Maria V ^a   Strukova, Elena N ^a   Vostrov, Sergey N ^a   Portnoy, Yury A ^a,b   Zinner, Stephen H ^c  

^a GAUSE INSTITUTE OF NEW ANTIBIOTICS   (Russian Federation)

^b P K ANOKHIN INSTITUTE OF NORMAL PHYSIOLOGY   (Russian Federation)

^c MOUNT AUBURN HOSPITAL   (United States)

Author keywords

Fluoroquinolones; In vitro dynamic models; Staphylococcal resistance

Indexed keywords

CIPROFLOXACIN;

ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIUM CULTURE; DRUG HALF LIFE; DRUG SENSITIVITY; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; HALF-LIFE; INFUSIONS, INTRAVENOUS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL;

EID: 55249124957     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.06.031     Document Type: Article

References (16)

1. Zhao X., and Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis 33 (2001) 147-156
2. Campion J.J., Chung P., McNamara P.J., Titlow W.B., and Evans M.E. Pharmacodynamic modeling of the evolution of levofloxacin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 49 (2005) 2189-2199
3. Campion J.J., McNamara P.J., and Evans M.E. Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments. Antimicrob Agents Chemother 48 (2004) 4733-4744
4. Firsov A.A., Vostrov S.N., Lubenko I.Y., Arzamastsev A.P., Portnoy Y.A., and Zinner S.H. ABT-492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model. J Antimicrob Chemother 54 (2004) 178-186
5. Firsov A.A., Vostrov S.N., Lubenko I.Y., Drlica K., Portnoy Y.A., and Zinner S.H. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother 47 (2003) 1604-1613
6. Firsov A.A., Vostrov S.N., Lubenko I.Y., Portnoy Y.A., and Zinner S.H. Prevention of the selection of resistant Staphylococcus aureus by moxifloxacin plus doxycycline in an in vitro dynamic model: an additive effect of the combination. Int J Antimicrob Agents 23 (2004) 451-456
7. Firsov A.A., Vostrov S.N., Lubenko I.Y., Zinner S.H., and Portnoy Y.A. Concentration-dependent changes in the susceptibility and killing of Staphylococcus aureus in an in vitro dynamic model that simulates normal and impaired gatifloxacin elimination. Int J Antimicrob Agents 23 (2004) 60-66
8. Zinner S.H., Lubenko I.Y., Gilbert D., Simmons K., Zhao X., Drlica K., et al. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. J Antimicrob Chemother 52 (2003) 616-622
9. Olofsson S.K., Marcusson L.L., Komp Lindgren P., Hughes D., and Cars O. Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration. J Antimicrob Chemother 57 (2006) 1116-1121
10. Olofsson S.K., Marcusson L.L., Stromback A., Hughes D., and Cars O. Dose-related selection of fluoroquinolone-resistant Escherichia coli. J Antimicrob Chemother 60 (2007) 795-801
11. Drlica K., Zhao X., Blondeau J.M., and Hesje C. Low correlation between MIC and mutant prevention concentration. Antimicrob Agents Chemother 50 (2006) 403-404
12. Dong Y., Zhao X., Domagala J., and Drlica K. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agents Chemother 43 (1999) 1756-1758
13. Wilson A.P.R., and Grüneberg R.N. Ciprofloxacin: 10 years of clinical experience (1997), Maxim Medical, Oxford, UK
14. Firsov A.A., Vostrov S.N., Shevchenko A.A., and Cornaglia G. Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model. Antimicrob Agents Chemother 41 (1997) 1281-1287
15. Firsov A.A., Shevchenko A.A., Vostrov S.N., and Zinner S.H. Inter- and intra-quinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept. Antimicrob Agents Chemother 42 (1998) 659-665
16. Firsov A.A., Zinner S.H., and Lubenko I.Y. In vitro dynamic models as tools to predict antibiotic pharmacodynamics. In: Nightingale C.H., Ambrose P.G., Drusano G.L., and Murakawa T. (Eds). Antimicrobial pharmacodynamics in theory and clinical practice. 2nd ed. (2007), Informa Healthcare USA, Inc., New York 45-78